{"product_id":"host-response-diagnostics-markets","title":"Host Response Diagnostics Markets 2027–2031","description":"\u003cp\u003e\u003cstrong\u003eHost Response Diagnostics Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027–2031\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGlobal forecasts by application, technology, care setting, test format and product, for 14 countries and regions, with 26 company profiles. Sepsis, bacterial vs viral and severity testing, beyond procalcitonin and routine inflammatory markers.\u003c\/p\u003e\n\u003cp\u003eSee the \u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0249\/8082\/files\/IDHOST_1126_Table_of_Contents.pdf?v=1793649467\" title=\"Host Response Diagnostics Markets Table of Contents\" target=\"_blank\" rel=\"noopener\"\u003eTable of Contents\u003c\/a\u003e. GET the \u003ca href=\"https:\/\/www.howesoundresearch.com\/pages\/get-a-detailed-table-of-contents-and-sample-pages-for-any-report\" title=\"Free sample\"\u003eFree Sample of this Report\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003eMany organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out \u003ca href=\"https:\/\/www.howesoundresearch.com\/pages\/get-a-detailed-table-of-contents-and-sample-pages-for-any-report\" title=\"Contact Us\"\u003eHere\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch3\u003eOur Take\u003c\/h3\u003e\n\u003cp\u003eHost-response tests read the patient's immune response instead of searching for the pathogen, and they answer the question clinicians face first: whether to treat, not what to treat. In 2026 the field became a market, with at least eight FDA-cleared or authorised products, its own billing codes and a Medicare add-on payment. It grows from $180.0 million in 2026 to $720.0 million in 2031, at 32.0% a year, as the same signatures move onto core-laboratory analysers, near-patient cartridges and fingerstick readers.\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0249\/8082\/files\/IDHOST_Key_Graphic.png?v=1793649467\" alt=\"Gene expression takes the lead: host response diagnostics market by technology, 2026 vs 2031\" width=\"100%\"\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMarket Size 2026:\u003c\/strong\u003e USD $180M   \u003cstrong\u003eMarket Size 2031:\u003c\/strong\u003e USD $720M   \u003cstrong\u003eCAGR:\u003c\/strong\u003e 32.0%\u003c\/p\u003e\n\u003ch3\u003eSituation Analysis: what is really happening\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe test leaves the emergency department. \u003c\/strong\u003eBeckman Coulter's Access MeMed BV won a CE mark under the IVDR in April 2026, putting a bacterial versus viral test on core-laboratory analysers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePoint-of-care arrives. \u003c\/strong\u003eLumos Diagnostics' FebriDx fingerstick test received a CLIA waiver and was live at 265 US sites by October; MeMed's BV Flex fingerstick test gained Breakthrough Device designation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayment is in place. \u003c\/strong\u003eMeMed BV, IntelliSep and TriVerity carry their own billing codes, paid at $260.50, $444.08 and $760.00 under the 2026 Medicare fee schedule, and TriVerity earns a new-technology add-on payment of up to $243.75 per case.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGene expression takes the lead. \u003c\/strong\u003eHost Gene Expression grows 36.8% a year and overtakes Host Protein Signatures in 2029; Near-Patient Cartridges add $350.1 million by 2031.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eThe guidelines lag the market. \u003c\/strong\u003eThe 2026 Surviving Sepsis Campaign guidelines found the evidence for novel host-response tests insufficient, so outcome studies decide who wins.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGovernment money matters. \u003c\/strong\u003ePrenosis paired a $20 million Series A with a $20 million BARDA contract, and the US Department of Defense sought host-based diagnostics for acute infection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0249\/8082\/files\/IDHOST_Application_Shift.png?v=1793649467\" alt=\"Sepsis and severity gain ground: host response diagnostics market by application, 2026 vs 2031\" width=\"100%\"\u003e\u003c\/p\u003e\n\u003ch3\u003eCompany Analysis: who is positioned, who is exposed\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eInflammatix, Cytovale, MeMed and Immunexpress: \u003c\/strong\u003eLeaders with FDA-cleared sepsis and bacterial versus viral tests.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBeckman Coulter, DiaSorin, Roche, Cepheid and Biocartis: \u003c\/strong\u003ePlatform partners that put host-response tests on installed analysers and cartridge systems.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ebioMérieux and Thermo Fisher: \u003c\/strong\u003eIncumbents whose procalcitonin tests are the price benchmark host-response tests must beat.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLumos Diagnostics, Abionic, Prenosis, SphingoTec, PHC and Bluejay Diagnostics: \u003c\/strong\u003ePoint-of-care tests, AI scores and novel single markers.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiomeme, Presymptom Health, Asep Medical, GNOMX, Loop Diagnostics, QuantuMDx, Cytomics and Endpoint Health: \u003c\/strong\u003eEmerging developers in the US, Europe and Asia.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBayesian Health: \u003c\/strong\u003eAI sepsis software that competes for the same triage decision without a specimen.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn all, 26 company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.\u003c\/p\u003e\n\u003ch3\u003eQuestions this report answers\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eHow large is the host-response diagnostics market, and how fast will it grow?\u003c\/li\u003e\n\u003cli\u003eWhich applications grow fastest: sepsis identification, bacterial versus viral, severity and prognosis, or TB?\u003c\/li\u003e\n\u003cli\u003eWill gene-expression, protein, cellular or algorithm-based tests win, and on which test format?\u003c\/li\u003e\n\u003cli\u003eWhat do billing codes, add-on payments, SEP-1 and the 2026 guidelines mean for adoption?\u003c\/li\u003e\n\u003cli\u003eWhich companies are best placed, and which depend on partners or new funding?\u003c\/li\u003e\n\u003cli\u003eHow large is each country market, and where is growth fastest?\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWhat's inside\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e292 pages, 23 chapters, 63 tables and 54 figures\u003c\/li\u003e\n\u003cli\u003eForecasts for 2027–2031 from a 2026 base year, by application, technology, care setting, test format and product, for 14 countries and regions\u003c\/li\u003e\n\u003cli\u003eSepsis identification and triage, bacterial versus viral differentiation, severity and prognosis, and technology platforms and test formats\u003c\/li\u003e\n\u003cli\u003eCare settings including military and TB triage, regulation, reimbursement and policy, international markets, and clinical evidence and health economics\u003c\/li\u003e\n\u003cli\u003e10 market-moving developments from 2026, SWOT, Porter's Five Forces and strategic recommendations\u003c\/li\u003e\n\u003cli\u003e26 company profiles\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0249\/8082\/files\/IDHOST_1126_Table_of_Contents.pdf?v=1793649467\" target=\"_blank\" rel=\"noopener\"\u003eDownload the Table of Contents (PDF)\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eWho buys this report\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiagnostic companies and business development teams: \u003c\/strong\u003esize the market, choose formats and find partners for host-response tests.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLaboratory and health-system leaders: \u003c\/strong\u003ejudge where host-response testing fits beside procalcitonin, culture and syndromic panels.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInvestors and analysts: \u003c\/strong\u003emodel a young, fast-growing market and the companies that depend on new funding.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntimicrobial stewardship and public health programmes: \u003c\/strong\u003eplan tests that cut unnecessary antibiotics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cb\u003eUse independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003eSee the \u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0249\/8082\/files\/IDHOST_1126_Table_of_Contents.pdf?v=1793649467\" title=\"Host Response Diagnostics Markets Table of Contents\" target=\"_blank\" rel=\"noopener\"\u003eTable of Contents\u003c\/a\u003e. GET the \u003ca href=\"https:\/\/www.howesoundresearch.com\/pages\/get-a-detailed-table-of-contents-and-sample-pages-for-any-report\" title=\"Free sample\"\u003eFree Sample of this Report\u003c\/a\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eABOUT THE LEAD AUTHOR\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0249\/8082\/files\/Powellcopy_480x480.png?v=1709168834\" alt=\"Greg Powell\" width=\"142\" height=\"177\"\u003e\u003c\/p\u003e\n\u003cp\u003eMr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:\u003c\/p\u003e\n\u003cp\u003eFinance for Senior Executives - \u003cstrong\u003eHarvard Business School\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMarket Research - \u003cstrong\u003eBurke Institute\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eM.B.A. (Finance and Policy) - \u003cstrong\u003eUniversity of British Columbia\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eB.Sc. (Chemistry) - \u003cstrong\u003eUniversity of British Columbia\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHe is an experienced business and clinical professional. He is co-author of the paper \"The Radioimmunoassay of Angiotensinogen by Antibody Trapping.\" He has worked in laboratory testing and management for over 20 years.\u003c\/p\u003e\n","brand":"Howe Sound Research","offers":[{"title":"Entire Report Single User","offer_id":68260913348721,"sku":null,"price":6995.0,"currency_code":"USD","in_stock":true},{"title":"Entire Report One to Five Users","offer_id":68260913381489,"sku":null,"price":9995.0,"currency_code":"USD","in_stock":true},{"title":"Entire Report Enterprise License","offer_id":68260913414257,"sku":null,"price":13995.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0249\/8082\/files\/IDHOST_1126_covercap.png?v=1793649467","url":"https:\/\/www.howesoundresearch.com\/products\/host-response-diagnostics-markets","provider":"Howe Sound Research","version":"1.0","type":"link"}